Form 4: Beam Therapeutics SVP, Finance and Treasurer Sells Shares to Cover Tax Obligations

Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics, sold 1,117 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Bethany J. Cavanagh, the SVP, Finance and Treasurer of Beam Therapeutics, sold 1,117 shares of common stock on January 2, 2025.
• The sale was executed to cover tax withholding obligations arising from the vesting of restricted stock units.
• The shares were sold at a weighted average price of $24.68, with individual transactions ranging from $24.21 to $25.02.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted before February 27, 2023.
• Following the transaction, Ms. Cavanagh directly owns 43,814 shares of Beam Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for corporate executives who receive equity compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate executives to avoid accusations of insider trading.
• The sale of shares to cover tax obligations is a standard practice in the industry.
• The price range of $24.21 to $25.02 is within the expected range for a stock sale of this type.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

Beam Therapeutics, insider trading, stock sale, Rule 10b5-1, tax obligations, equity compensation, executive transaction